Table 1

Haemodynamic indices, functional status and right heart function at baseline and at 3 months follow-up after BPA treatment

VariableBaselineFollow-upP value
Haemodynamics
 RAP, mm Hg9.4±4.15.1±2.7<0.0001
 RVEDP, mm Hg12.4±5.76.4±2.5<0.0001
 mPAP, mm Hg44.7±11.034.4±8.3<0.0001
 COTD, L/min4.4±1.14.8±1.10.03
 PVRTD, dyn.s/cm5663±281436±196<0.0001
Functional status
 VO2 max, mL/min/kg16.9±3.418.9±4.50.002
 VE/VCO255.3±12.245.0±7.80.03
 6MWT, metres366±107440±94<0.0001
 WHO FC ≥3, n (%)24 (80)4 (13)<0.0001
 CAMPHOR symptom score8.7±5.45.6±6.10.0005
Right heart function
 NT pro-BNP, pg/mL442 (168,1607)202 (105 to 447)<0.0001
 RV d mid-diameter, cm4.4±1.03.8±0.70.002
 RV d area, cm231.9±7.628.2±7.40.003
 RV FAC, %24.4±6.231.3±9.10.0001
 RV systolic velocity, cm/s11.5±3.013.2±3.20.03
 Diastolic EI1.3±0.31.1±0.20.001
 Systolic EI1.5±0.51.3±0.40.004
  • BPA, balloon pulmonary angioplasty; CAMPHOR, Cambridge Pulmonary Hypertension Outcome Review; COTD, cardiac output by thermodilution; d, diastolic; EI, Eccentricity Index; FAC, fractional area change; mPAP, mean pulmonary artery pressure; 6MWT, 6 min walk test; NT-Pro BNP, N-terminal probrain natriuretic peptide; PVRTD, pulmonary vascular resistance by thermodilution; RAP, right atrial pressure; RV, right ventricular; RVEDP, right ventricular end-diastolic pressure; VE/VCO2, minute ventilation/ carbon dioxide production (ventilator efficiency); VO2, oxygen consumption; WHO FC, WHO functional class.